Sagimet Biosciences Inc. (SGMT)

NASDAQ: SGMT · USD

$10.7

+0.32 (+3.1%)· Recorded snapshot

Market cap	761.6M
Net income (ttm)	-47.1M
EPS (ttm)	-$1.25
Shares out	70.9M
Volume	938,042
Beta	3.49

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -47.1M
EPS (ttm): -$1.25
Market cap: 761.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-24.4

P25 n/aP50 n/aP75 n/a

ROIC-16.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All SGMT indicators

Market & fundamental data

Available fields

175

Groups with data

Currency

USD

Showing 175 of 175 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001400118
Company name	Sagimet Biosciences Inc.
Country	United States
Country code	US
CUSIP number	786700104
Earnings date	2026-11-12
Earnings time	bmo
Employees	16
Employees change	2
Employees growth	14.29%
Enterprise value	$505.9M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2006
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2023-07-14
Is primary listing	Yes
Is SPAC	No
ISIN number	US7867001049
Last 10-K release date	2026-03-11
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$761.6M
Market cap category	Small-Cap
Next earnings date	2026-11-12
Options	Yes
Price	$10.74
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	SGMT
U.S. state	California
Website	https://www.sagimet.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-11.63%
FCF / EV yield	-8.32%
FCF yield	-5.51%
Forward EV/Sales	279.88x
Forward P/S	422.49x
P/B ratio	2.51x
Price / tangible book value	2.96x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-2.9M
ROA	-16.41%
ROA (5Y)	-29.43%
ROCE	-20.4%
ROE	-24.37%
ROE (5Y)	-46.86%
ROIC	-16.94%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	4
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-52.6M
EPS	$-1.25
FCF per share	$-0.59
Financing cash flow	$164.7M
Free cash flow	$-41.7M
Free cash flow minus SBC	$-50.6M
Investing cash flow	$629,000
Net cash flow	$123.6M
Net income	$-47.1M
Operating cash flow minus SBC	$-50.6M
Operating income	$-52.6M
Stock-based compensation	$8.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$4.15
Debt / equity	0.01
Long-term assets	$19.4M
Long-term liabilities	$1.9M
Net cash (debt)	$255.6M
Net cash / market cap	33.75%
Net cash growth	88.91%
Net debt / equity	-1
Piotroski F-Score	2
Property, plant and equipment	$2M
Shareholders' equity	$256.2M
Tangible book value	$256.2M
Tangible book value per share	$4.15
Total assets	$263.4M
Total cash	$240.1M
Total debt	$1.9M
Total liabilities	$7.3M
WACC	23.37%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$244M
Current liabilities	$5.4M
Current ratio	45.02
Net working capital	$-1.5M
Quick ratio	44.31
Working capital	$238.6M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-17.03%
Dividend yield	0%
Shareholder yield	-17.03%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$8.08
1D price change	3.07%
1M price change	14.07%
1M total return	14.07%
1W price change	8.21%
1W total return	8.21%
1Y price change	22.56%
1Y return CAGR	22.58%
1Y total return	22.56%
20-day SMA	$9.11
200-day SMA	$7.46
3M price change	41.48%
3M total return	41.48%
3Y price change	184.1%
3Y return CAGR	41.62%
3Y total return	184.1%
50-day SMA	$9.94
50-day SMA vs 200-day SMA	50over200
52-week high	$11.45
52-week high date	2026-09-10
52-week low	$4.50
52-week low date	2026-03-30
6M price change	29.8%
6M total return	29.8%
All-time high	$20.71
All-time high date	2024-01-22
All-time low	$1.73
All-time low date	2025-04-07
Average true range (ATR)	$0.63
Average volume	1.3M
Beta (1Y)	2.68
Beta (2Y)	2.7
Beta (5Y)	3.49
Change from 52-week high	-6.19%
Change from 52-week low	138.67%
Change from all-time high	-49.11%
Change from all-time low	509.25%
Change from open	4.47%
Day's gap	-1.34%
Dollar volume	$10.1M
High price	$10.75
Low price	$10.28
Monthly RSI	56.78
Open price	$10.28
Position in 52-week range	97.87%
Premarket change	0%
Premarket close	$10.42
Premarket price	$10.42
Premarket volume	10K
Previous close	$10.42
Price vs 150-day SMA	30.48%
Price vs 20-day SMA	15.71%
Price vs 200-day SMA	41.34%
Price vs 50-day SMA	6.07%
Relative volume	0.71
Return from IPO open	-31.1%
Return from IPO price	-33.25%
RSI	60.97
Sharpe ratio	0.59
Sharpe ratio (3Y)	0.72
Sortino ratio	1.09
Sortino ratio (3Y)	1.64
Volume	938K
Weekly RSI	61.13
YTD price change	78.04%
YTD total return	78.04%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	64.5M
Float percentage	91.01%
Shares change (QoQ)	63.13%
Shares change (YoY)	17.03%
Shares held by insiders	0.96%
Shares held by institutions	71.19%
Shares outstanding	70.9M
Short % of float	17.86%
Short % of shares	16.26%
Short ratio	8.3 days

Deeper analysis on SGMT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this SGMT report

Is a complete SGMT research report available?

No complete published report is available for Sagimet Biosciences Inc. (SGMT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Sagimet Biosciences Inc. (SGMT)

Price

Financial snapshot

Fair-value bridge

Latest news · SGMT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All SGMT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on SGMT

Frequently asked questions